(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 September 2025 (18.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/194162 A1

(51) International Patent Classification:
A61K 9/127 (2025.01) *A61K 47/36* (2006.01)
A61K 31/519 (2006.01) *A61P 17/02* (2006.01)
A61K 9/08 (2006.01) *A61P 31/04* (2006.01)
A61K 47/10 (2017.01) *A61P 35/00* (2006.01)
A61K 47/26 (2006.01)

(21) International Application Number:
PCT/US2025/020193

(22) International Filing Date:
17 March 2025 (17.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/566,193 15 March 2024 (15.03.2024) US

(71) Applicant: **ELUCIDERM INC.** [US/US]; 7163 Torrey Mesa Court, San Diego, California 92129 (US).

(72) Inventor: **HOLSWORTH, Daniel D.**; c/o Eluciderm Inc., 7163 Torrey Mesa Court, San Diego, California 92129 (US).

(74) Agent: **ADAMS, Michael J.** et al.; SQUIRE PATTON BOGGS (US) LLP, 555 California Street, Suite 550, San Francisco, California 94104 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: PHARMACEUTICAL COMPOSITIONS OF WNT PATHWAY INHIBITORS FOR WOUND TREATMENT



FIG. 14

(57) Abstract: A pharmaceutical composition comprising a WNT inhibitor, a glycol, one or more solubilizers, and saline or water. The pharmaceutical composition optionally comprises a graphene oxide-hyaluronic acid conjugate, one or more phospholipids, one or more carriers, stabilizer, buffer, and/or preservative. The pharmaceutical composition is suitable for topical administration.

WO 2025/194162 A1

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*